You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed neuroblastoma

Showing 1 - 25 of 5,715
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma Trial (GPC2 CAR T cells)

Not yet recruiting
  • Refractory Neuroblastoma
  • +2 more
  • GPC2 CAR T cells
  • (no location specified)
Dec 21, 2022

Relapsed Neuroblastoma Trial in Grand Rapids (Cerebral Spinal (CS) radiation, Focal radiotherapy (SRS))

Withdrawn
  • Relapsed Neuroblastoma
  • Cerebral Spinal (CS) radiation
  • Focal radiotherapy (SRS)
  • Grand Rapids, Michigan
    Helen DeVos Children's Hospital
Apr 20, 2022

Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma Trial in Atlanta (Ex Vivo Expanded Allogeneic ?d T Cells in

Not yet recruiting
  • Neuroblastoma
  • +2 more
  • Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
  • Atlanta, Georgia
    Children's Healthcare of Atlanta
Oct 6, 2022

Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Dallas (131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf)

No longer available
  • Relapsed Neuroblastoma
  • Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine
  • +2 more
  • Dallas, Texas
    The University of Texas Southwestern Medical Center
Apr 13, 2022

Neuroblastoma, Medulloblastoma Trial in United States (Nifurtimox, Cyclophosphamide, Topotecan)

Completed
Has Results
  • Neuroblastoma
  • Medulloblastoma
  • San Diego, California
  • +14 more
Dec 28, 2022

Relapsed Neuroblastoma, Refractory Neuroblastoma Trial (Natural Killer Cells, Temozolomide, Irinotecan)

Recruiting
  • Relapsed Neuroblastoma
  • Refractory Neuroblastoma
  • Natural Killer Cells
  • +4 more
  • Columbus, Ohio
    Nationwide Children's Hospital
Oct 26, 2022

Relapsed Neuroblastoma Trial in Minsk (DNA vaccine, Salmonella oral vaccine, Lenalidomide)

Recruiting
  • Relapsed Neuroblastoma
  • DNA vaccine
  • +2 more
  • Minsk, Minsk Region, Belarus
    Belarussian Research Center for Pediatric Oncology, Hematology a
Mar 1, 2022

Neuroblastoma Trial in United States (TPI 287, Temozolomide, Irinotecan)

Terminated
Has Results
  • Neuroblastoma
  • TPI 287
  • +2 more
  • Phoenix, Arizona
  • +7 more
Apr 20, 2022

Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma Trial in United States (67Cu-SARTATE, 64Cu-SARTATE)

Recruiting
  • Neuroblastoma
  • +2 more
  • Phoenix, Arizona
  • +8 more
Jun 29, 2022

B7-H3-positive Relapsed/ Refractory Neuroblastoma Trial in Tianjin (T cell injection targeting FLT3 chimeric antigen receptor)

Not yet recruiting
  • B7-H3-positive Relapsed/ Refractory Neuroblastoma
  • T cell injection targeting FLT3 chimeric antigen receptor
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Nov 1, 2022

Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)

Recruiting
  • Neuroblastoma Recurrent
  • Natural killer cell
  • +4 more
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
Feb 22, 2023

Neuroblastoma Trial in Wien, Greifswald (dinutuximab beta)

Active, not recruiting
  • Neuroblastoma
  • dinutuximab beta
  • Wien, Austria
  • +1 more
Oct 1, 2021

Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Minneapolis (131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium

Recruiting
  • Relapsed Neuroblastoma
  • Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine (131I-MIBG)
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota Masonic Cancer Center
Jan 20, 2022

Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Neuroblastoma
  • Osteosarcoma
  • iC9.GD2.CAR.IL-15 T-cells
  • +2 more
  • Atlanta, Georgia
  • +1 more
Jan 4, 2023

High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma Trial in Canada, United States (Dinutuximab,

Recruiting
  • High Risk Neuroblastoma
  • +4 more
  • Biospecimen Collection
  • +6 more
  • Los Angeles, California
  • +10 more
Jan 19, 2023

Neuroblastoma, Pediatric Solid Tumor Trial in Boston (procedure, biological, drug)

Recruiting
  • Neuroblastoma
  • Pediatric Solid Tumor
  • Tissue collection
  • +3 more
  • Boston, Massachusetts
  • +1 more
Oct 17, 2022

Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma Trial in Houston (C7R-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Relapsed Neuroblastoma
  • +6 more
  • C7R-GD2.CART cells
  • +2 more
  • Houston, Texas
  • +1 more
Nov 12, 2021

Neuroblastoma Trial (Topotecan, Temozolomide, Ribociclib)

Not yet recruiting
  • Neuroblastoma
  • (no location specified)
Jun 17, 2022

Neuroblastoma in Children Trial in Guangzhou (Tucidinostat and etoposide)

Recruiting
  • Neuroblastoma in Children
  • Tucidinostat and etoposide
  • Guangzhou, China
    Sun Yat-sen University
Jun 9, 2022

Neuroblastoma Trial in Houston (iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan)

Active, not recruiting
  • Neuroblastoma
  • iC9-GD2 T Cells - frozen
  • +5 more
  • Houston, Texas
  • +1 more
Jan 4, 2023

Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors Trial in Roma (GD2-CART01)

Recruiting
  • Neuroblastoma
  • +5 more
  • GD2-CART01
  • Roma, Italy
    Ospedale Pediatrico Bambino Gesù
Mar 9, 2022

Neuroblastoma Trial in Canada, United States (Sorafenib, Cyclophosphamide, Topotecan)

Active, not recruiting
  • Neuroblastoma
  • Los Angeles, California
  • +11 more
Jan 30, 2023

Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8 With GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 2, 2022

Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)

Terminated
  • Neuroblastoma
  • +2 more
  • Humanized 3F8 Bispecific Antibody
  • Blood draw
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 11, 2022